Shots:

• The P-II study evaluated the safety and tolerability of paxalisib (60 mg QD) vs temozolomide at US (6 sites) in 30 patients with unmethylated MGMT newly diagnosed glioblastoma
• Result: 60mg QD MTD dose defined; mOS (n=30): 15.7 mos. vs 12.7mos. mPFS (n=30): 8.4mos. vs. 5.3mos. In mITT (n=27) OS: 15.9mos.
• Kazia plans to report the final result in Q1’22. In 2022 investigators are also planning to submit and publish a manuscript to a peer-reviewed academic journal

Ref: PR Newswire | Image: Kazia